Mutations of Janus kinase 2 (JAK2), predominantly JAK2V617F, are discovered in ~95% of patients with polycythemia vera and 50–60% of patients with essential thrombocythemia, as well as primary myelofibrosis (MF) [3–6]. This evidence concerns the gene JAK2 and acquired polycythemia vera.